omkar kanike

8/4/2019 omkar kanike

1/20


2/20

CONTENTSo Aim and plan of work

o Introduction about Niosomes

o Structure & advantages of Niosomes

o Materials & Methodso Preparation of Niosomes

o Evaluation of Niosomes

o Results & Discussion

o Conclusiono References


3/20

Aim & plan of work

Aceclofenac is a narrow therapeutic index &short biological half-life

This Study main aim is improve the

bioavailability Drug is encapsulated in vesicle,so surviving

period also inreased in blood

Effect of different surfactants & their

concentrations on drug release from thevesicles


4/20

INTRODUCTION

o Niosomes are a novel drug delivery system, in which themedication is encapsulated in a vesicle.

o very small, and microscopic in size. Their size lies in thenanometric scale.

o Niosomes are unilamellar or multilamellar vesicles. Thevesicle is composed of a bilayer of non-ionic surface activeagents and hence the name niosome.

o A diverse range of materials have been used to formniosomes such as sucrose ester surfactants andpolyoxyethylene alkyl ether surfactants, alkyl ester, alkylamides, fatty acids and amino acid compound.


5/20

STRUCTURE OF NIOSOME

The admixture of non-ionic surfactant of the alkyl or dialkylpolyglycerol ether class and cholesterol with subsequent hydration inaqueous media.

The bilayer in the case of niosomes is made up of non-ionic surfaceactive agents rather than phospholipids as seen in the case ofliposomes.

Most surface active agents when immersed in water yield micellarstructures, however some surfactants can yield bilayer vesicles whichare niosomes..

The niosome is made of a surfactant bilayer with its hydrophilic endsexposed on the outside and inside of the vesicle, while thehydrophobic chains face each other within the bilayer.


6/20

Hence, the vesicle holds hydrophilic drugs within the space enclosed inHence, the vesicle holds hydrophilic drugs within the space enclosed in the vesicle, while hydrophobic drugs are embedded within the bilayer itself.the vesicle, while hydrophobic drugs are embedded within the bilayer itself.


7/20

Advantages ofNiosomes

Accommodate hydrophilic, lipophilic as well as ampiphilic drugmoieties.

Depot to release the drug slowly and of controlled release.

They are osmotically active and stable.

They increase the stability of the entrapped drug .

Handling and storage of surfactants easy.

Can increase the oral bioavailability of drugs .

Route of administration (all types).

Surfactants (Biodegrable,Biocompatable,non immunogenic).

Protection from Biolo ical environment.


8/20

Material & Methods

Aceclofenac from Rantus Pharmaceuticals

Spans from Rolex chemical industry

Diethylether,methanol,pdp,sodium hydroxide fromS.D.Fine Chemicals.


9/20

Preparation of Niosomes

Modified ether injection Method:- Cholesterol+Surfactant .

2 ml ethanol

Dissolved

+Aceclofenac

6 ml diethyl ethermixing

Resulting solution

injected into


10/20


11/20

EVALUATION

Entrapment efficiency:- Exhaustive dialysis

Method.


12/20

Particle shape & Size

Size distribution of NSF-3 and NSF-6


13/20

Fig.: Microphotographs of NSF-3 and microphotograph of NSF-6.


14/20

.

.

Evaluation Parameters of Niosomes


15/20

In vitro Dissolution studies

MEMBRANE DIFFUSION

TECHNIQUE:-

5ml of sample werewithdrawn periodically &same volume replaced by

fresh medium

274 nm

Samples analysed andoptical density were foundin uv visiblespectrophotometer


16/20


17/20


18/20

Conclusion

The present study demonstrated the successful preparation ofAceclofenac niosomes and their evaluation.

Formulation NSF-6 showed high entrapment efficiency (96.07%0.35),particle size (4.220.47m) and drug release (87.21%) over 72 h.

Hence it was considered to be good niosomal formulation with greaterbioavailability


19/20

References

M.Mlathotra,N.K Jain.Indian Drugs

G.H.Buckton Interfacial phenomena in Drug Delivery andTargeting.Academic plablisher Switzerland

N.K.Jain,controlled &Novel Drug Delivery,1st edition,publishedby CBS publishers & Distributors,New Delhi;

http://www.intaspharm.com/aceclofenac/2009.

.chemilland21.com/arokorh/lifesciences/phar/aceclofenac i


20/20

Documents

omkar kanike